News
4th China Pharma IP Summit 2019 |
| 4th China Pharma IP Summit 2019 (CPIPS2019) will be held on 23rd -25th , Oct this year at Primus Hotel Shanghai Hongqiao China. As a dedicated event to pharmaceutical intellectual property, In the past three years we gathered more than 1000 attendees from relevant government departments(CNIPA/EPO/JPO/USPTO), industry associations, global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers and so on. Our topics covered the IP protection in all over the world, include mainly China, Europe, US, Japan, South Korea and India. We hope CPIPS could be a good networking and sharing platform for Industry peers, in which we are promoting industry innovation and development. Part of Confirmed Speakers Snapshots : Join US To Meet: 40+ Experts from Government & Authoritative Organizations Give Speeches 200+ Leading China Local & Multinational Pharmaceutical/Biotech Companies 80+ Leading China Local & Foreign Law Firms/IP Agencies 500+ Attendees Following the latest development of China Patent Law Amendment, IP Enforcement, Patent Linkage, Patent Term Extension Reform, and related Drug Regulatory Updates in China Addressing Challenges and Uncertainties under BREXIT, SPC, Unitary Patent & UPC in Europe Understanding the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other key regions Learning IP management and practical experiences from Global and China leading pharma companies Meeting your clients/partners face to face and interact with 450+ industry peers Topics Will be Presented and Discussed: The Present Situation & Trends of Patent Examination and Hotspot Issues in Reexamination and Invalidation Cases in China IP Enforcement and Protection in China Interpretation: The Latest Drug Regulatory Policies and Implementing Details from National Medical Products Administration The Impact of Patent Linkage and Patent Term Extension System on the Industry Patent Protection of Biological Sequences Data Supplementation for Chemical and Biotech Patents IP Challenges and Strategy from Perspective of Innovative Pharma Company under New Environment in China Hot Issues and Difficulties in Pharma Patent Infringement Litigation Cases Evaluation of Inventive Step of Pharmaceutical Compound Inventions Latest Developments of IPR and Recent Patent Invalidation Cases in US The Strategy of ANDA Filers to Challenge Patents Under a PIV Certification and Recent ANDA Litigation Cases Study Identifying the Loss of Exclusivity (LoE) of a U.S. Pharmaceutical Patent Portfolio U.S. Biosimilar Patent Litigation: Strategies and Trends Panel Discussion IP Issues Related to US and China (Strategy and Challenges) UPC and UPS - Why does it Make Sense for Europe and What Could be the Impact of Brexit? Recent European Regulatory Developments on Supplementary Protection Certificates (SPCs) Biosimilars in US,EU and China: Where Are We Now and Where Are We Going? How to Build a Successful Licensing Program and Other Strategies for IP Monetization Patent System and Practice of Medical Fields and Patent Term Extension in Japan IP Management & Practices Adopted by Generic Drug Manufacturers from India Patent System for Pharmaceutical Invention in South Korea Life Sciences: IP and Regulatory Environment in Brazil and selected Latin American Jurisdictions Current Patenting Situation of Chinese Medicine in China & Analysis from Reexamination and Invalidation Cases Rethinking of Patent Creative Evaluation for Traditional Chinese Medicine Relevant Issues on the Protection of Trade Secrets of Traditional Chinese Medicine IP Challenges and Strategy for Chinese Medicine ‘Going Out’ |
Rm1907, Unit 2,Building NO.3,NO.1, BeiQing,ChangPing,Beijing 102206,P.R.China
Tel:86-10-62119266 Fax:86-10-62110146
E-mail: mail@justalen.com 京ICP备09085994号-2
Copyright © Beijing Justalen Intellectual Property Law Firm